Improving Drug Development Requires More Data Sharing – AAMC/FDA Report
This article was originally published in The Pink Sheet Daily
Executive Summary
Developing new mechanisms to share data across industry, FDA, NIH and academia will be vital to improving drug development, says a report summary of January meeting.
You may also be interested in...
FTC Suffers Reversal On “Reverse Payments” Enforcement
The Solicitor General says the Supreme Court should not hear the Commission's appeal of a case brought against Schering-Plough regarding a generic drug settlement.
AstraZeneca Collaborations Moving From “Deals” To “Relationships”
Fox Chase Cancer Center’s Weeks concurs that umbrella agreements with pharma and biotech companies are becoming more common.
Pharmacogenetic Dosing Recommendations Sorely Needed By Clinicians, Formularies, SACGHS Says
Tests are currently available to identify patient responders, but clinicians need guidance on how to adjust dosing for them, the HHS Secretary's Advisory Committee on Genetics, Health & Society agreed.